VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Monday, December 29, 2025
Stock Comparison
Unicharm Corporation vs Amgen Inc.
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
Unicharm Corporation
8113 · Tokyo Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Unicharm Corporation's moat claims, evidence, and risks.
View 8113 analysisAmgen Inc.
AMGN · Nasdaq Stock Market
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Comparison highlights
- Moat score gap: Amgen Inc. leads (70 / 100 vs 60 / 100 for Unicharm Corporation).
- Segment focus: Unicharm Corporation has 5 segments; Amgen Inc. has 3 segments (80.1% in Core Innovative Medicines).
- Primary market structure: Oligopoly vs Competitive. Pricing power: Moderate vs Moderate.
- Moat breadth: Unicharm Corporation has 7 moat types across 3 domains; Amgen Inc. has 5 across 3.
Primary market context
Unicharm Corporation
Baby and Child Care Products
Disposable baby diapers and baby wipes
Japan, Asia, Middle East, and selected other markets
Consumers (parents/caregivers)
Branded manufacturer
Amgen Inc.
Core Innovative Medicines
Branded biopharmaceutical therapies for common diseases (bone health, inflammation, oncology, cardiovascular and other specialty areas)
Global
Payers, providers, and pharmacies
Drug developer/manufacturer
80.1%
Side-by-side metrics
Moat coverage
Shared moat types
Unicharm Corporation strengths
Amgen Inc. strengths
Segment mix
Unicharm Corporation segments
Full profile >Baby and Child Care Products
Oligopoly
Feminine Care Products
Oligopoly
Wellness Care Products (Adult Incontinence)
Oligopoly
Pet Care Products
Competitive
Industrial Materials and Other Businesses
Competitive
Amgen Inc. segments
Full profile >Core Innovative Medicines
Competitive
Rare Disease Portfolio (Horizon + others)
Quasi-Monopoly
Biosimilars
Oligopoly
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.